Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide
Primary Purpose
Akathisia, Nausea
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
metoclopramide 10 mg
Sponsored by
About this trial
This is an interventional prevention trial for Akathisia focused on measuring metoclopramide, akathisia, nausea, vomiting, antiemetic, improvement of nausea
Eligibility Criteria
Inclusion Criteria:
- Patients 18 through 65 years of age and 50-90 kg of weight who presented to the ED with primary or secondary complaints of moderate to severe nausea who not use of commonly accepted antiemetic within the previous 24 hours were eligible for this study.
- Their peripheral oxygen saturation level was 90% or over while respirating room air and free of any respiratory problems.
Exclusion Criteria:
- Patients with mild symptoms of nausea
- Altered mental status
- Abnormal vital signs
- Any known allergy to the metoclopramide
- Previously enrolled in the study
- Known renal failure or insufficiency
- GIS hemorrhage, ileus and/or perforation
- Women who were pregnant and lactating
- Those with a history of epilepsy
- Admitted to the ED due to acute psychiatric symptoms
- Restless legs syndrome
- Parkinson
- Organic brain disease
- Phaeochromocytoma
- Patient with alcohol
- Anticholinergic, sedative, hypnotic, trankilizan, digoxin, cimetidine, tetracycline and levo-dopa use
- Presence of severe agitation akathisia can not be evaluated and uncooperative individuals.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
2 minutes bolus infusion
15 minutes slow infusion
Arm Description
Outcomes
Primary Outcome Measures
akathisia and nausea scores
Secondary Outcome Measures
Full Information
NCT ID
NCT01069536
First Posted
February 16, 2010
Last Updated
February 16, 2010
Sponsor
Pamukkale University
1. Study Identification
Unique Protocol Identification Number
NCT01069536
Brief Title
Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide
Study Type
Interventional
2. Study Status
Record Verification Date
March 2007
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
March 2007 (Actual)
Study Completion Date
May 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Pamukkale University
4. Oversight
5. Study Description
Brief Summary
Study Objective:
The purpose of this study is to compare the effects of metoclopramide administration in bolus versus slow infusion medications in ED patients complaining of nausea for the determination of the therapeutic effect and prevention of akathisia.
Methods:
This was a prospective, randomized, double-blind trial. The investigation was held between 01 March 2007 and 01 May 2008, in the Emergency Department of Pamukkale University Faculty of Medicine. The patients with moderate to severe nausea randomized and divided into two groups as for the previously planned administration type of drug. Ten mg metoclopramide was administered in one group with slow infusion (SIG) in 15 minutes, via 2 minutes bolus infusion (BIG) into the other group. Whole procedure was observed, akathisia and nausea scores and vital changes were recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Akathisia, Nausea
Keywords
metoclopramide, akathisia, nausea, vomiting, antiemetic, improvement of nausea
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
140 (Actual)
8. Arms, Groups, and Interventions
Arm Title
2 minutes bolus infusion
Arm Type
Active Comparator
Arm Title
15 minutes slow infusion
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
metoclopramide 10 mg
Primary Outcome Measure Information:
Title
akathisia and nausea scores
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients 18 through 65 years of age and 50-90 kg of weight who presented to the ED with primary or secondary complaints of moderate to severe nausea who not use of commonly accepted antiemetic within the previous 24 hours were eligible for this study.
Their peripheral oxygen saturation level was 90% or over while respirating room air and free of any respiratory problems.
Exclusion Criteria:
Patients with mild symptoms of nausea
Altered mental status
Abnormal vital signs
Any known allergy to the metoclopramide
Previously enrolled in the study
Known renal failure or insufficiency
GIS hemorrhage, ileus and/or perforation
Women who were pregnant and lactating
Those with a history of epilepsy
Admitted to the ED due to acute psychiatric symptoms
Restless legs syndrome
Parkinson
Organic brain disease
Phaeochromocytoma
Patient with alcohol
Anticholinergic, sedative, hypnotic, trankilizan, digoxin, cimetidine, tetracycline and levo-dopa use
Presence of severe agitation akathisia can not be evaluated and uncooperative individuals.
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide
We'll reach out to this number within 24 hrs